RhoVac AB

NGM:RHOVAC Stock Report

Market Cap: SEK 22.1m

RhoVac Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lars Hedbys

Chief executive officer

SEK 191.6k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure4yrs

Recent management updates

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12
We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27
RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23
Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08
We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

CEO

Lars Hedbys (65 yo)

less than a year

Tenure

SEK 191,610

Compensation

Mr. Lars Hedbys, Ph. D., served as Director at Hamlet Pharma AB (publ) until 2022. He serves as Independent Chairman of the Board of Directors at Scandinavian ChemoTech AB (publ) since 2020. He serves as D...

Board Members

NamePositionTenureCompensationOwnership
Lars Hedbys
Acting CEO & Director8yrsSEK 191.61kno data
Per Straten
Scientific Advisor & Co-Founderno datano datano data
Lars Hockenstrom
Director3yrsSEK 191.61kno data
Cristina Glad
Director8yrsSEK 160.69kno data
Gunnar Gardemyr
Chairman5yrsSEK 383.22kno data
Georg Holländer
Scientific Advisory Board2.3yrsno datano data
Anne Ridley
Member of Scientific Advisory Board2.9yrsno datano data
Per-Anders Abrahamsson
Scientific advisorno datano datano data
Klaus Brasso
Scientific Advisorno datano datano data

4.0yrs

Average Tenure

65.5yo

Average Age

Experienced Board: RHOVAC's board of directors are considered experienced (4 years average tenure).